Medicinal Chemistry News and Research RSS Feed - Medicinal Chemistry News and Research

Enhancements to Reaxys Medicinal Chemistry address workflow, data challenges of early drug discovery

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced enhancements to Reaxys Medicinal Chemistry that address the critical workflow and data challenges of early drug discovery. [More]
Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics, Inc. announces the receipt of a Phase II SBIR grant in the amount of $1.54 million dollars from the U.S. National Institutes of Health to advance its novel Re-engineering with Metabolism Preserved (RAMP) medicinal chemistry program. [More]
Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry. [More]
Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

As a tumor grows, its cancerous cells ramp up an energy-harvesting process to support its hasty development. This process, called autophagy, is normally used by a cell to recycle damaged organelles and proteins, but is also co-opted by cancer cells to meet their increased energy and metabolic demands. [More]
University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

The Feinstein Institute for Medical Research and Molecular Medicine announced today that the fourth Anthony Cerami Award in Translational Medicine will be conferred to Thomas E. Starzl, MD, PhD, professor of surgery at the University of Pittsburgh School of Medicine. The award is in recognition of his research in organ transplantation and alloengraftment mechanisms. [More]
Purdue University-led study could lead to better treatments for people infected with MERS virus

Purdue University-led study could lead to better treatments for people infected with MERS virus

A Purdue University-led team of researchers studying the Middle East Respiratory Syndrome, or MERS, have found molecules that shut down the activity of an essential enzyme in the virus and could lead the way to better treatments for those infected. [More]
ExCellThera's stem cell expansion approach may benefit AML patients undergoing transplants

ExCellThera's stem cell expansion approach may benefit AML patients undergoing transplants

Patients suffering from acute myeloid leukemia, who require stem cell transplantation as part of their treatment,may now benefit from a new best-in-class process that improves the viability and success of cord blood stem cell transplantation. [More]
Experimental drug improves failing heart's function

Experimental drug improves failing heart's function

An experimental drug improves the ability of heart muscle cells damaged by heart failure to pump blood, according to the results of a study led by Icahn School of Medicine at Mount Sinai researchers and published online today in Nature Communications. [More]
Researchers uncover critical role for two proteins in chromatin structure

Researchers uncover critical role for two proteins in chromatin structure

A team of researchers at the IRCM led by François Robert, PhD, uncovered a critical role for two proteins in chromatin structure. Their breakthrough, recently published in the scientific journal Molecular Cell, helps explain how DNA is organized in our cells. This discovery could lead to a better understanding of what causes certain types of cancer, such as lymphoma. [More]
Study expands understanding of the production of ET-743 compound

Study expands understanding of the production of ET-743 compound

For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells. The drug has been approved for use in patients in Europe and is in clinical trials in the U.S. [More]
Researchers explore how low-level electrical stimulation reduces inflammation

Researchers explore how low-level electrical stimulation reduces inflammation

The Feinstein Institute for Medical Research, the research arm of the North Shore-LIJ Health System, and SetPoint Medical Inc., a biomedical technology company, today released the results of research on the therapeutic potential of vagus nerve stimulation. In a paper published by Bioelectronic Medicine, Kevin J. Tracey, MD, and his colleagues at the Feinstein Institute, explore how low-level electrical stimulation interacts with the body's nerves to reduce inflammation, a fundamental goal of bioelectronic medicine. [More]
New compound offers longer lasting painkilling effects

New compound offers longer lasting painkilling effects

Medications have long been used to treat pain caused by injury or chronic conditions. Unfortunately, most are short-term fixes or cause side effects that limit their use. Researchers at the University of Missouri have discovered a new compound that offers longer lasting painkilling effects, and shows promise as an alternative to current anesthetics. [More]
TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance. [More]
Purdue University study sheds light on how decitabine drug reverses cell damage

Purdue University study sheds light on how decitabine drug reverses cell damage

A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment. [More]
Scientists identify chemical compounds that block cancer-causing oncoprotein

Scientists identify chemical compounds that block cancer-causing oncoprotein

A team of scientists at the University of Kansas has pinpointed six chemical compounds that thwart HuR, an "oncoprotein" that binds to RNA and promotes tumor growth. [More]
Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing. [More]
Purdue researchers identify new class of chemical insecticides to control mosquitoes

Purdue researchers identify new class of chemical insecticides to control mosquitoes

Purdue researchers have identified a new class of chemical insecticides that could provide a safer, more selective means of controlling mosquitoes that transmit key infectious diseases such as dengue, yellow fever and elephantiasis. [More]
NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

The National Institutes of Health has awarded Dr. Walter Fast, associate professor of medicinal chemistry at The University of Texas at Austin's College of Pharmacy, a four-year $2.1 million grant to develop small-molecules that counter antibiotic resistance in Gram-negative bacteria. If successful, the research could lead to new drugs for treating bacterial infections that are resistant to most antibiotics. [More]
Researchers develop 'warhead' molecule that targets deadly bacteria, spares healthy cells

Researchers develop 'warhead' molecule that targets deadly bacteria, spares healthy cells

Targeting deadly, drug-resistant bacteria poses a serious challenge to researchers looking for antibiotics that can kill pathogens without causing collateral damage in human cells. [More]
Lucideon welcomes University College Dublin students on work placements

Lucideon welcomes University College Dublin students on work placements

Lucideon is pleased to announce that it has offered three healthcare technology placements to students from University College Dublin (UCD). [More]
Advertisement
Advertisement